[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2016001204A - Vectores virales adeno-asociados (aav) utiles para transducir tejido adiposo. - Google Patents

Vectores virales adeno-asociados (aav) utiles para transducir tejido adiposo.

Info

Publication number
MX2016001204A
MX2016001204A MX2016001204A MX2016001204A MX2016001204A MX 2016001204 A MX2016001204 A MX 2016001204A MX 2016001204 A MX2016001204 A MX 2016001204A MX 2016001204 A MX2016001204 A MX 2016001204A MX 2016001204 A MX2016001204 A MX 2016001204A
Authority
MX
Mexico
Prior art keywords
adeno
associated viral
adipose tissue
trasducing
aav
Prior art date
Application number
MX2016001204A
Other languages
English (en)
Inventor
Verónica Jiménez Cenzano
Fàtima Bosch Tubert
Original Assignee
Uni Autònoma De Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni Autònoma De Barcelona filed Critical Uni Autònoma De Barcelona
Publication of MX2016001204A publication Critical patent/MX2016001204A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01002—Glucokinase (2.7.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a vectores virales adeno-asociados útiles para transducir tejido adiposo. La invención también se refiere a polinucleótidos, plásmidos, vectores y métodos para la producción de estos vectores virales adeno-asociados. La invención también se refiere a métodos de terapia génica útiles para el tratamiento de una enfermedad que requiere la regulación de los niveles de expresión de un gen.
MX2016001204A 2012-08-02 2013-08-02 Vectores virales adeno-asociados (aav) utiles para transducir tejido adiposo. MX2016001204A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382314.8A EP2692868A1 (en) 2012-08-02 2012-08-02 Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
PCT/EP2013/066271 WO2014020149A1 (en) 2012-08-02 2013-08-02 Adeno-associated viral (aav) vectors useful for trasducing adipose tissue

Publications (1)

Publication Number Publication Date
MX2016001204A true MX2016001204A (es) 2016-07-21

Family

ID=46785347

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001204A MX2016001204A (es) 2012-08-02 2013-08-02 Vectores virales adeno-asociados (aav) utiles para transducir tejido adiposo.

Country Status (8)

Country Link
US (2) US10711281B2 (es)
EP (1) EP2692868A1 (es)
JP (1) JP6450758B2 (es)
CA (1) CA2919363C (es)
CH (1) CH710197B1 (es)
DE (1) DE112013007239T5 (es)
MX (1) MX2016001204A (es)
WO (1) WO2014020149A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2960912A1 (en) 2014-09-16 2016-03-24 Universitat Autonoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
WO2016087678A1 (en) * 2014-12-05 2016-06-09 Universitat Autònoma De Barcelona Viral vectors for the treatment of diabetes
ES2900973T3 (es) 2015-01-07 2022-03-21 UNIV AUTòNOMA DE BARCELONA Constructo genético de vector individual que comprende genes de insulina y glucoquinasa
US12065673B2 (en) * 2015-07-10 2024-08-20 Etablissement Francais Du Sang Method for obtaining human brown/beige adipocytes
SG10201912703PA (en) 2015-10-01 2020-02-27 Goleini Inc Targeted expression of chloride channels and methods of use thereof
US11401527B2 (en) 2016-04-17 2022-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods useful for prophylaxis of organophosphates
EP3609524A4 (en) * 2017-04-14 2021-01-27 Rhode Island Hospital VEGF GENE THERAPY FOR TENDON AND TENDON INJURIES
US10898585B2 (en) 2017-04-14 2021-01-26 Ptc Therapeutics .Inc. Gene therapy for AADC deficiency
CN110913886A (zh) * 2017-05-24 2020-03-24 巴塞罗那自治大学 包含成纤维细胞生长因子21(fgf21)编码序列的病毒表达构建体
IL306098A (en) * 2017-05-24 2023-11-01 Univ Barcelona Autonoma Viral expression vectors containing the coding sequence for FIBROBLAST GROWTH FACTOR 21 (FGF21)
TW202428875A (zh) * 2017-07-31 2024-07-16 香港商映像生物有限公司 用於靶向ｃｙｐ４ｖ２基因及治療結晶樣視網膜色素變性之核酸分子
JP2020533968A (ja) * 2017-08-25 2020-11-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 組換えアデノ随伴ベクター
JP2018198611A (ja) * 2018-08-03 2018-12-20 ウニベルシダッド アウトノマ デ バルセロナ 脂肪組織に形質導入するのに有用なアデノ随伴ウイルスベクター
WO2021007473A1 (en) 2019-07-10 2021-01-14 Masonic Medical Research Institute Vgll4 with ucp-1 cis-regulatory element and method of use thereof
JP2023524010A (ja) * 2020-04-28 2023-06-08 プレジデント アンド フェローズ オブ ハーバード カレッジ 高効率遺伝子送達系
US20230212610A1 (en) * 2021-12-20 2023-07-06 DNARx Nucleic acid expression using subcutaneous administration
WO2023129947A2 (en) * 2021-12-29 2023-07-06 Salk Institute For Biological Studies Methods of lowering blood glucose and treating type 2 diabetes by activation of pde4d3
CN115154422B (zh) * 2022-07-28 2023-07-07 四川大学 Cd44靶向和ros响应的纳米胶束药物组合物及制备方法与应用
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5446143A (en) 1993-09-14 1995-08-29 Board Of Regents, The University Of Texas System Adipose-specific promoter region of human aromatase cytochrome P450 gene
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
JPH11507231A (ja) 1995-06-07 1999-06-29 イェール ユニバーシティ アデノ関連ウイルスベクターの経口送達
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US5869037A (en) 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US6521225B1 (en) 1996-09-06 2003-02-18 Chiron Corporation AAV vectors
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US20030219409A1 (en) 1997-01-10 2003-11-27 Biovex Limited Eukaryotic gene expression cassette and uses thereof
NZ500546A (en) 1997-04-14 2001-09-28 Cell Genesys Inc Methods for increasing the production of high titre stocks of recombinant adeno-associated virus (AAV)
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
DE69829471T2 (de) 1997-05-13 2006-04-13 University Of North Carolina At Chapel Hill Auf lentivirus basierende gentransfer-vektoren
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6136597A (en) * 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
WO1999061643A1 (en) 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
US6555342B1 (en) 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
ES2288037T3 (es) 1998-11-05 2007-12-16 The Trustees Of The University Of Pennsylvania Secuencia de acido nucleico del serotipo 1 de adenovirus asociado, vectores y celulas huesped que las contienen.
ATE454445T1 (de) 1998-11-10 2010-01-15 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
DE19909769A1 (de) 1999-03-05 2000-09-07 Bundesrepublik Deutschland Let Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
DK1204739T3 (da) 1999-08-09 2008-10-20 Targeted Genetics Corp Forögelse af ekspression af en enkeltstrenget, heterolog nukleotidsekvens fra rekombinante, virale vektorer ved en sådan udformning af sekvensen at den danner intrastrengbasepar
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
AU5557501A (en) 2000-04-28 2001-11-12 Univ Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
DE60139471D1 (de) 2000-06-01 2009-09-17 Univ North Carolina Verfahren und zusammensetzungen zur kontrollierter abgabe von rekombinant parvovirus vektoren
AU2001267058A1 (en) 2000-06-09 2001-12-17 University Of Florida Research Foundation, Inc. Aav vector-based compositions and therapeutic uses thereof
ES2170720B1 (es) 2000-12-20 2003-12-16 Univ Barcelona Autonoma Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.
US7319002B2 (en) 2001-08-08 2008-01-15 The Trustees Of The University Of Pennsylvania Method for purification of viral vectors having proteins which bind sialic acid
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
BR122016004944B8 (pt) 2001-11-13 2021-07-27 Univ Pennsylvania vírus adenoassociado recombinante, célula hospedeira procariótica, composição e método de geração do referido vírus
DK1453547T3 (en) 2001-12-17 2016-12-05 Univ Pennsylvania ADENOASSOCATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING THESE AND APPLICATIONS THEREOF
ES2664505T3 (es) 2001-12-17 2018-04-19 The Trustees Of The University Of Pennsylvania Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas
ES2280694T3 (es) 2002-04-29 2007-09-16 The Trustees Of The University Of Pennsylvania Metodo para la extraccion directa y la amplificacion de virus integrados del adn celular de tejidos.
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
WO2004020600A2 (en) 2002-08-28 2004-03-11 University Of Florida Modified aav
ES2648241T3 (es) 2003-09-30 2017-12-29 The Trustees Of The University Of Pennsylvania Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos
WO2005037232A2 (en) 2003-10-17 2005-04-28 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
EP3603676A1 (en) 2005-04-07 2020-02-05 The Trustees of the University of Pennsylvania Method of increasing the function of an aav vector
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
US20090317417A1 (en) 2006-04-28 2009-12-24 The Trustees Of The University Of Pennsylvania Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof
ES2400235T3 (es) 2006-04-28 2013-04-08 The Trustees Of The University Of Pennsylvania Método de producción escalable de AAV
ATE502121T1 (de) 2006-06-06 2011-04-15 Massachusetts Inst Technology Cholesterinregulierender komplex aus sirt1 und lxr und seine verwendung
US20100111873A1 (en) 2007-02-20 2010-05-06 Russell Stephen J Treating cancer with viral nucleic acid
AR066354A1 (es) 2007-05-01 2009-08-12 Genzyme Corp La terapia sistematica con factor-1 de crecimiento de tipo insulina reduce la neuropatia periferica diabetica y mejora la funcion renal en la nefropatia diabetica
WO2009140206A1 (en) 2008-05-11 2009-11-19 The Gov. Of The U. S. A., As Represented By The Secretary Of The Dept. Of Health And Human Services Improved expression of il-12 family heterodimers
JPWO2010010887A1 (ja) * 2008-07-24 2012-01-05 塩野義製薬株式会社 組織発現プロモーター
CN101790147A (zh) 2009-01-23 2010-07-28 华为技术有限公司 计费信息关联方法及系统
GB0903207D0 (en) 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
EP2394667A1 (en) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
EP2605798A1 (en) 2010-07-12 2013-06-26 Universidad Autònoma de Barcelona Gene therapy composition for use in diabetes treatment
CN104520421B (zh) * 2011-10-28 2017-05-24 北卡罗来纳-查佩尔山大学 用于生产腺伴随病毒的细胞系
EP2492347A1 (en) 2012-05-22 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Methods for the production of vectors
KR102446169B1 (ko) 2014-05-14 2022-09-22 에스테베 파마슈티칼스 에스에이 리소좀 저장 장애의 치료를 위한 아데노연관 바이러스 벡터
EP3101125A1 (en) 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
AU2017333336B2 (en) 2016-09-30 2023-11-09 Esteve Pharmaceuticals, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses

Also Published As

Publication number Publication date
CA2919363C (en) 2023-02-21
US10711281B2 (en) 2020-07-14
DE112013007239T5 (de) 2016-04-07
JP6450758B2 (ja) 2019-01-09
US20160319303A1 (en) 2016-11-03
WO2014020149A1 (en) 2014-02-06
CH710197B1 (de) 2017-11-30
US11629361B2 (en) 2023-04-18
US20200270640A1 (en) 2020-08-27
EP2692868A1 (en) 2014-02-05
CA2919363A1 (en) 2014-02-06
JP2016525361A (ja) 2016-08-25

Similar Documents

Publication Publication Date Title
MX2016001204A (es) Vectores virales adeno-asociados (aav) utiles para transducir tejido adiposo.
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
MX2022012490A (es) Vectores de aav para la terapia genica de la retina y el snc.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
EA201692361A1 (ru) Лентивирусные векторы
MX2018005145A (es) Terapia genetica.
NZ708144A (en) Recombinant adenoviruses and use thereof
SG10201803384TA (en) Bispecific t cell activating antigen binding molecules
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
MX2015014423A (es) Administración efectiva de genes grandes por vectores aav duales.
MX2015014464A (es) Vectores para terapia genica para tratar cardiomiopatía.
MX2020010694A (es) Particulas de raav que codifican mir-708 y usos del mismo.
GB201009222D0 (en) Improved cancer therapy based on tumour associated antigens derived from cyclin D1
CL2020001948A1 (es) Terapia génica para la distrofía muscular de cinturas tipo 2c.
EP3148569A4 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
EP3998341A3 (en) Adenoviral vectors
BR112018011838A2 (pt) terapia gênica para distúrbios oculares
IN2014MN00246A (es)
ZA201803080B (en) Methods of treating muscular dystrophy
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
NZ765719A (en) Adeno-associated virus (aav) vector having hybrid hgf gene introduced thereto
NZ704280A (en) Baclofen and acamprosate based therapy of macular degeneration disorders
PH12017501872A1 (en) Methods of treating diseases
CL2022000292A1 (es) Partículas virales para uso en el tratamiento de sinucleinopatías tales como enfermedad de parkinson mediante terapia genética
TN2016000460A1 (en) Aav vectors for retinal and cns gene therapy.